Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Determine Flu Vaccine Suppliers For 2005-2006 Season In January

Executive Summary

FDA will decide whether Chiron can produce flu vaccine for next season by Jan. 5, Acting Commissioner Lester Crawford, PhD, said Nov. 18

You may also be interested in...



ID Biomedical Opens Channel For Fluviral Distribution in U.S.

Henry Schein has committed to purchasing approximately half of all ID Biomedical Fluviral doses produced for the U.S. under a distribution agreement for the flu vaccine unveiled by the companies Dec. 6

ID Biomedical Seeking FluINsure Development Partner For U.S. Market

ID Biomedical is seeking a development partner for securing U.S. approval of its inactived intranasal flu vaccine FluINsure, President Todd Patrick said

FDA Approves Use Of Fluarix Under An IND; GSK To Submit BLA In First Half ’05

GlaxoSmithKline plans to establish a presence in the U.S. influenza vaccine market with a BLA submission for Fluarix in the first half of 2005

Related Content

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel